| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CASI Pharmaceuticals, Inc.$0.21
-0.13 (-38.97%)
D 38Pipeline Score Undervalued Pharma · Clinical
Market Cap
3.21 M
EPS
-3.16
P/E Ratio
-
Value Trade
3.01 M
-75.31 %
Week
-78.39 %
1 Month
-81.72 %
3 Month
-91.53 %
6 Month
-99.18 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
9.96 M
52 Week Range
0.21 - 3.09
% held by Insiders
87.27 %
% held by Institutions
32.6 %
Enterprise Value
17.38 M
Total Shares
20.55 M
Short %
1.78 %
Float Shares
5.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D38
Pipeline Score $28M
Pipeline ValueUndervalued
Valuation Signal11
Drugs Scored8.7x
rNPV / MCap Top 52%
Micro Cap (rank 435 of 905)
Percentile RankCASI Pharmaceuticals, Inc. faces pipeline headwinds (38/100), with $2.2B risk-adjusted pipeline value, led by 2-methoxyestradiol in Relapsed Multiple Myeloma (Phase 2), across $147B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2-methoxyestradiol Small molecule | Relapsed Multiple Myeloma | Phase 2 | NCT00592579 | 10% | $591M | COMPLETED | 60 | - | - | Sep 1, 2008 | - | Feb 26, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CID-103 | chronic immune thrombocytopenia (ITP) | Phase 1 | 2025-09-09 | |||
CID-103 | chronic immune thrombocytopenia (ITP) | Phase 1 | 2025-09-09 | |||
CID-103 | chronic immune thrombocytopenia (ITP) | Phase 1 | 2025-09-09 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CASI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CASI Pharmaceuticals, Inc. (CASI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CASI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CASI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CASI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CASI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CASI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CASI ranks across every disease it competes inCompetitive Position is a premium feature
See how CASI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial